Intravitreous Aflibercept Injection in Pachychoroid Neovascu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to compare the 12-month efficacy of intravitreous aflibercept (IVA) injection between eyes with pachychoroid neovasculopathy and neovascular age-related macular degeneration (AMD).

Retrospective, comparative case series analysis included 27 eyes with pachychoroid neovasculopathy and 63 with neovascular AMD. All patients received three initial monthly, followed by bimonthly, IVA injections.

Results:
--12 months after initial treatment, the mean best-corrected visual acuity (BCVA) had improved both in pachychoroid neovasculopathy (from 0.28 to 0.14 logMAR) and neovascular AMD (from 0.40 to 0.29 logMAR).

--12 months after initial treatment, eyes with pachychoroid neovasculopathy exhibited decreased mean central retinal thickness (CRT) and subfoveal choroidal thickness and presence of polyps and improved integrity of external limiting membrane (ELM) and ellipsoid zone band.

--At the 12-month follow-up, 77% and 68% of eyes with pachychoroid neovasculopathy and neovascular AMD, respectively, exhibited dry macula. Baseline CRT was correlated with 12-month BCVA in eyes with pachychoroid neovasculopathy.

--In eyes with neovascular AMD, CRT and presence of intact ELM were significant predictors of 12-month BCVA.

Finally, in eyes of pachychoroid neovasculopathy and neovascular AMD, periodic IVA injection improves anatomical and functional outcomes.

Source: https://www.dovepress.com/effects-of-intravitreous-aflibercept-injection-in-pachychoroid-neovasc-peer-reviewed-article-OPTH
Like
Comment
Share